Generative AI Use Cases: Build vs Buy for Pharmaceutical Teams

Generative AI Use Cases are advancing from departmental experiments to platforms that may touch discovery evidence, clinical documents, safety records, regulatory dossiers, and manufacturing investigations. That transition forces a practical architecture decision: should a research-based biopharmaceutical company build a domain platform around general-purpose models, or buy a specialized pharmaceutical system? The choice cannot be settled by a feature demonstration. It depends on evidence traceability, GxP impact, integration depth, internal capability, and the degree to which the workflow differentiates the company.

A rigorous assessment of Generative AI Use Cases should begin with the decision being improved, not with the model being offered. Target validation, protocol design, safety case processing, eCTD authoring, deviation investigation, and technology transfer have different source data, failure consequences, and review accountabilities. A build strategy may offer precision and control, whereas a specialized product may accelerate deployment through established workflow components. Neither is universally superior.

Defining the Two Options Before Comparing Them

In the build option, the company assembles its own application layer using selected foundation models, retrieval services, knowledge graphs, identity controls, evaluation pipelines, and user interfaces. Building rarely means training a frontier model from scratch. It usually means creating proprietary orchestration around internal scientific and regulated content, then integrating it with systems such as electronic laboratory notebooks, clinical repositories, safety databases, regulatory document platforms, quality systems, and manufacturing historians.

The buy option uses a vendor platform designed for pharmaceutical workflows. Depending on the product, it may include preconfigured document ingestion, scientific search, safety extraction, regulatory templates, validation documentation, audit logging, or connectors to common life-sciences systems. Configuration is still required. Terminology, roles, approval paths, retention policies, data boundaries, and intended-use controls must reflect the sponsor's processes, so buying does not eliminate implementation work.

A third pattern often emerges in practice: a governed enterprise AI foundation combined with specialized applications for selected functions. The comparison remains useful because every use case still involves a build-versus-buy decision at some layer. A company may build its discovery knowledge environment while buying case-intake automation, or buy a regulatory authoring product while building proprietary CMC intelligence around its process history.

Criteria Matrix for Generative AI Use Cases

The following matrix summarizes the default trade-offs. These are starting positions rather than fixed truths; vendor maturity, internal engineering strength, therapeutic modality, geographic footprint, and existing architecture can reverse an apparent advantage.

• Strategic differentiation: Build is favored when proprietary data, scientific reasoning, or workflow design creates portfolio advantage. Buy is favored for standardized activities where execution quality matters more than uniqueness.
• Time to initial value: Buy usually leads when a product has relevant connectors and workflow components. Build can move quickly for a narrow prototype but often slows during integration, security review, validation, and production hardening.
• Evidence traceability: Build offers direct control over retrieval, citations, and logging. Buy may provide mature traceability out of the box, but the sponsor must verify that it reaches the source granularity required for the intended use.
• GxP validation: Build gives the company full responsibility for specifications, testing, change control, and monitoring. Buy may supply qualification evidence, although the regulated company retains responsibility for fitness for use.
• Integration depth: Build generally handles idiosyncratic data models and legacy systems better. Buy performs well when supported connectors match the deployed technology stack.
• Model flexibility: Build makes it easier to route tasks among models or replace components. Buy simplifies model management but can restrict portability and transparency.
• Lifecycle cost: Build requires sustained product, engineering, validation, and support capacity. Buy converts some costs into subscription and services fees, with potential increases as users, data volumes, or modules expand.
• Deployment risk: Build concentrates delivery risk internally. Buy introduces vendor viability, roadmap, subcontractor, hosting, data-use, and lock-in risks.

The matrix reveals why total cost of ownership is more complex than license cost versus developer salaries. A serious estimate includes source-system integration, data remediation, taxonomy work, cybersecurity controls, validation, user support, evaluation maintenance, model consumption, vendor oversight, and change control. It should also include the cost of delay. Saving twelve months in protocol feasibility or regulatory assembly can matter more than a modest difference in annual platform expenditure.

Generative AI Use Cases with high reuse deserve special attention. A governed retrieval and evaluation layer built for clinical study reports might later support safety narratives, medical information responses, and health-authority questions. Conversely, a specialized product may spread faster across affiliates because it already supports multilingual content, regional controls, and common submission formats. The architecture team should identify which capabilities are reusable platform services and which belong inside a specific functional application.

Discovery and Clinical Development: Where Building Can Differentiate

AI Drug Discovery is a strong candidate for selective building because internal data and scientific practice can be genuinely differentiating. A company's assay history, negative results, chemical series, translational models, and target hypotheses encode knowledge that no vendor can supply. A custom environment can represent relationships among targets, pathways, structures, experimental conditions, ADME/Tox observations, and candidate-selection criteria. It can also use company-specific vocabulary and preserve the lineage from generated hypothesis to underlying experiment.

However, building the full stack is rarely necessary. Commodity capabilities such as document parsing, chemical structure handling, literature indexing, model hosting, or laboratory connectors may be purchased. The differentiating layer is the way those components support target-to-hit identification, hit-to-lead progression, lead optimization, and candidate nomination. A useful system should help medicinal chemists and biologists choose informative experiments, not merely produce plausible molecular designs.

Clinical Development AI presents a more balanced decision. Protocol intelligence can benefit from proprietary recruitment history, screen-failure reasons, site performance, amendment patterns, and indication strategy. A custom application may model how eligibility criteria affect the addressable population and connect those findings with operational feasibility. Yet commercial platforms can offer mature access to external trial information, standardized protocol structures, and established site-selection workflows that would be costly to reproduce.

For clinical data management, biostatistics, and study closeout, the case for buying becomes stronger when processes are standardized and systems are widely used. Even then, sponsor-specific controls remain essential. Generated query suggestions, deviation summaries, analysis descriptions, and report sections must align with the approved protocol, data-management plan, statistical analysis plan, and controlled outputs. Generative AI Use Cases that affect interpretation of efficacy or safety require explicit human review regardless of sourcing model.

Safety and Regulatory Affairs: Standardization Favors Specialized Products

Pharmacovigilance AI often favors specialized products because the workflow is structured, high volume, multilingual, and tightly controlled. Vendors may already support document intake, entity extraction, duplicate checks, coding assistance, narrative drafting, seriousness assessment prompts, and routing to a safety database. Those capabilities can reduce labor in case processing and literature surveillance, particularly when configured for the sponsor's products, listedness references, reporting rules, and medical-review practices.

The buy advantage is not automatic. A safety organization must test performance on difficult source material, pregnancy cases, follow-up correspondence, literature reports, combination products, and cases containing multiple suspect drugs or events. It must verify that the system preserves source facts, distinguishes missing information from negative findings, and does not silently normalize ambiguity. SAE and SUSAR reporting timelines make reliability and exception handling as important as average extraction accuracy.

Regulatory dossier authoring also has substantial standardized content, making specialized platforms attractive. Products may provide eCTD-aware templates, content reuse, structured authoring, terminology controls, and claim-to-source traceability. For an NDA or BLA, those functions can reduce manual reconciliation across modules and make late updates easier to assess. A buyer should inspect how the platform handles effective versions, reused content, tables, cited evidence, reviewer comments, and health-authority response commitments.

A build strategy remains compelling for proprietary regulatory intelligence. A company may want to connect agency questions, precedents, commitments, label negotiations, and internal response strategies across programs. That corpus is sensitive and highly contextual. Building the intelligence layer while buying the publishing and document-control capabilities can preserve strategic knowledge without recreating mature submission infrastructure. This hybrid pattern is often more defensible than forcing one option across the full regulatory lifecycle.

Quality, Provenance, and Inspection Readiness

Quality assurance should evaluate the intended use before deciding how much assurance evidence is necessary. A discovery literature assistant used for exploratory work has a different risk profile from a system that drafts a GMP deviation impact assessment. For regulated applications, teams need approved requirements, data-flow documentation, access controls, audit trails, test evidence, change management, incident procedures, and periodic review. The vendor can contribute evidence, but the pharmaceutical company remains responsible for demonstrating fitness for its process.

Generated text also requires provenance controls. Teams may use AI-generated text detectors when triaging uncontrolled external content, but classification cannot establish scientific validity or authorship history. Inspection-ready control comes from recording the source documents retrieved, the model and version used, the relevant configuration, the generated output, subsequent edits, and named reviewer approval. A confident detection score does not provide that chain of evidence.

Building provides maximum control over these records, although control has value only when the company funds the required engineering and governance. Buying may provide better logging and validation support than an immature internal platform. Due diligence should therefore include a technical demonstration using realistic evidence, review of the supplier's development and quality practices, security assessment, subcontractor transparency, business-continuity planning, and contractual notice for material model or infrastructure changes.

Generative AI Use Cases should be evaluated with task-specific test sets rather than generic language benchmarks. A regulatory application needs tests for unsupported claims, outdated sources, cross-document inconsistency, and omission of qualifying evidence. A safety application needs medically reviewed cases and error-severity grading. A quality application needs deviations with known investigation outcomes, including examples where no definitive root cause was established. The objective is not eloquence; it is dependable support for the regulated decision.

CMC and Manufacturing: Integration Depth Changes the Answer

CMC applications sit between proprietary knowledge and repeatable workflows. Technology transfer, process validation, analytical method transfer, specification setting, and commercial scale-up depend heavily on product- and site-specific evidence. A build approach can connect development reports, batch records, process characterization, stability studies, deviations, CAPAs, and process analytical technology data in a model tailored to the company's modality and manufacturing network.

Specialized products can still accelerate document review, batch-record checks, investigation assembly, and knowledge retrieval. A system might compare an executed record against the master instructions, identify missing entries, retrieve similar deviations, and prepare an event chronology. It should not infer a root cause merely because a prior investigation looks similar. Process engineers, quality control, and quality assurance must verify the evidence, assess impact on critical quality attributes, approve CAPA, and retain authority over lot disposition.

Pharmaceutical AI Solutions are most attractive here when they support both unstructured documents and structured process data. A language-only product may summarize investigation reports while missing the time-series pattern that explains the event. Conversely, an internally built analytics model may detect drift but fail to connect it with material genealogy, operator notes, or approved procedures. The strongest architecture combines domain retrieval, statistical or mechanistic analysis, and governed narrative generation.

Integration cost can dominate this decision. Manufacturing sites may have different historians, laboratory systems, electronic batch records, naming conventions, and levels of data maturity. A vendor's standard connector may work at one site and require substantial customization at another. The selection team should test a representative brownfield site rather than extrapolating from a modern pilot facility. Generative AI Use Cases must survive local complexity if they are expected to support a global network.

A Practical Decision Framework for Portfolio Selection

The first decision question is whether the workflow creates strategic differentiation. Proprietary target reasoning, translational insight, and portfolio-specific regulatory intelligence often justify internal ownership. More standardized functions such as document classification, safety intake, submission formatting, and basic batch-record review may favor buying. The second question is whether a qualified product already matches the source systems, terminology, and control requirements. If heavy customization is unavoidable, the apparent speed advantage may disappear.

The third question concerns internal capability over the full lifecycle. Building requires more than data scientists. It needs product ownership, domain experts, data engineering, security, platform reliability, model evaluation, user support, and GxP validation where applicable. Those resources must persist after launch as models, regulations, source systems, and workflows change. Buying shifts some of this burden, but supplier management, configuration ownership, process validation, and performance monitoring remain internal responsibilities.

The fourth question is reversibility. Pharmaceutical AI Solutions should allow the company to export its content, metadata, evaluation sets, feedback, and audit history in usable formats. Contracts should address model training on customer data, retention, geographic processing, subcontractors, service termination, and transition support. Architectures should separate proprietary knowledge from replaceable model components where practical. This reduces lock-in and makes future model changes manageable.

Finally, sponsors should use evidence gates. Begin with representative retrospective data, measure against an expert baseline, and grade errors by consequence. Then run a prospective pilot with human review before expanding scope. Metrics should reflect the workflow: hypothesis turnaround and experimental yield in discovery; protocol cycle time and recruitment forecast accuracy in clinical development; case quality and processing time in safety; evidence reconciliation in regulatory affairs; or investigation time and recurrence in manufacturing.

When the Hybrid Model Wins

For many large biopharmaceutical companies, the durable answer will be hybrid. An enterprise foundation can provide identity, access, approved models, retrieval standards, logging, evaluation, and monitoring. Functional teams can then build proprietary reasoning layers or deploy specialized vendor products on that foundation. Shared controls reduce duplication, while local product ownership preserves the distinctions among medicinal chemistry, clinical operations, pharmacovigilance, regulatory affairs, medical affairs, and quality.

The hybrid model also supports portfolio sequencing. Teams can buy a mature application to relieve an immediate safety or authoring bottleneck, while building a strategic discovery knowledge environment over a longer horizon. They can replace a model without reconstructing the user workflow, or replace a vendor module without losing the governed evidence layer. This modularity matters because both foundation models and pharmaceutical software markets will evolve faster than validated processes can be redesigned.

Generative AI Use Cases should therefore be mapped as capabilities, data dependencies, controls, and decisions rather than collected as a list of chatbot ideas. That map makes reuse visible and exposes where a vendor claim depends on unavailable data. It also helps leadership fund the unglamorous components—document quality, metadata, identity, evaluation, and change control—that determine whether a pilot becomes a reliable production service.

Conclusion

Generative AI Use Cases in pharmaceuticals do not support a universal build-or-buy verdict. Build is strongest where proprietary evidence and scientific reasoning create differentiation; buy is strongest where mature, standardized workflow components can shorten deployment; and hybrid architecture often provides the best balance. Sponsors should compare options using traceability, GxP impact, integration depth, lifecycle capability, reversibility, and measurable workflow value. When evaluating Pharmaceutical AI Solutions, the decisive question is not whether the software can generate convincing content, but whether it can support an accountable pharmaceutical decision with controlled evidence.